date,title,source
Oct-22-18,"Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist",PR Newswire
Nov-13-18,Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies,PR Newswire
Nov-14-18,Migraine-Focused Biotech Has A Headache On Quarterly Losses,Investor's Business Daily
Nov-14-18,Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results,PR Newswire
Nov-15-18,Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant,PR Newswire
Nov-20-18,"Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018",PR Newswire
Nov-26-18,"Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)",PR Newswire
